200 related articles for article (PubMed ID: 11245550)
1. Contraception with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
Wildemeersch D; Schacht E
Eur J Contracept Reprod Health Care; 2000 Dec; 5(4):234-40. PubMed ID: 11245550
[TBL] [Abstract][Full Text] [Related]
2. Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
Wildemeersch D; Schacht E
Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):93-101. PubMed ID: 11518454
[TBL] [Abstract][Full Text] [Related]
3. Treatment of primary and secondary dysmenorrhea with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
Wildemeersch D; Schacht E; Wildemeersch P
Eur J Contracept Reprod Health Care; 2001 Dec; 6(4):192-8. PubMed ID: 11848648
[TBL] [Abstract][Full Text] [Related]
4. Contraception and treatment in the perimenopause with a novel "frameless" intrauterine levonorgestrel-releasing drug delivery system: an extended pilot study.
Wildemeersch D; Schacht E; Wildemeersch P
Contraception; 2002 Aug; 66(2):93-9. PubMed ID: 12204781
[TBL] [Abstract][Full Text] [Related]
5. The effect on menstrual blood loss in women with uterine fibroids of a novel "frameless" intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
Wildemeersch D; Schacht E
Eur J Obstet Gynecol Reprod Biol; 2002 Apr; 102(1):74-9. PubMed ID: 12039094
[TBL] [Abstract][Full Text] [Related]
6. Endometrial suppression with a new 'frameless' levonorgestrel releasing intrauterine system in perimenopausal and postmenopausal women: a pilot study.
Wildemeersch D; Schacht E
Maturitas; 2000 Jul; 36(1):63-8. PubMed ID: 10989243
[TBL] [Abstract][Full Text] [Related]
7. Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles.
Pakarinen PI; Suvisaari J; Luukkainen T; Lähteenmäki P
Fertil Steril; 1997 Jul; 68(1):59-64. PubMed ID: 9207585
[TBL] [Abstract][Full Text] [Related]
8. Intrauterine contraception in the year 2001: can intrauterine device use be revived with new improved contraceptive technology?
Wildemeersch D; Schacht E; Thiery M; Van Kets H
Eur J Contracept Reprod Health Care; 2000 Dec; 5(4):295-304. PubMed ID: 11245557
[TBL] [Abstract][Full Text] [Related]
9. Hormonal intrauterine devices.
Rybo G; Andersson K; Odlind V
Ann Med; 1993 Apr; 25(2):143-7. PubMed ID: 8489751
[TBL] [Abstract][Full Text] [Related]
10. The Femilis LNG-IUS: contraceptive performance-an interim analysis.
Wildemeersch D; Janssens D; Andrade A
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):103-10. PubMed ID: 19340705
[TBL] [Abstract][Full Text] [Related]
11. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia.
Irvine GA; Campbell-Brown MB; Lumsden MA; Heikkilä A; Walker JJ; Cameron IT
Br J Obstet Gynaecol; 1998 Jun; 105(6):592-8. PubMed ID: 9647148
[TBL] [Abstract][Full Text] [Related]
12. Performance and acceptability of intrauterine release of levonorgestrel with a miniature delivery system for hormonal substitution therapy, contraception and treatment in peri and postmenopausal women.
Wildemeersch D; Schacht E; Wildemeersch P
Maturitas; 2003 Mar; 44(3):237-45. PubMed ID: 12648887
[TBL] [Abstract][Full Text] [Related]
13. Assessment of menstrual blood loss in Brazilian users of the frameless copper-releasing IUD with copper surface area of 330 mm2 and the frameless levonorgestrel-releasing intrauterine system.
Andrade AT; Souza JP; Andrade GN; Rowe PJ; Wildemeersch D
Contraception; 2004 Aug; 70(2):173-7. PubMed ID: 15288225
[TBL] [Abstract][Full Text] [Related]
14. Progesterone/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding.
Lethaby AE; Cooke I; Rees M
Cochrane Database Syst Rev; 2000; (2):CD002126. PubMed ID: 10796865
[TBL] [Abstract][Full Text] [Related]
15. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.
Luukkainen T; Toivonen J
Contraception; 1995 Nov; 52(5):269-76. PubMed ID: 8585882
[TBL] [Abstract][Full Text] [Related]
16. Review of clinical experience with the frameless LNG-IUS for contraception and treatment of heavy menstrual bleeding.
Wildemeersch D; Andrade A
Gynecol Endocrinol; 2010 May; 26(5):383-9. PubMed ID: 20192899
[TBL] [Abstract][Full Text] [Related]
17. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
[TBL] [Abstract][Full Text] [Related]
18. Menstrual blood loss in women using the frameless FibroPlant LNG-IUS.
Andrade A; Wildemeersch D
Contraception; 2009 Feb; 79(2):134-8. PubMed ID: 19135571
[TBL] [Abstract][Full Text] [Related]
19. Continuous combined parenteral estrogen substitution and intrauterine progestogen delivery: the ideal HST combination?
Wildemeersch D; Janssens D; Weyers S
Maturitas; 2005 Jun; 51(2):207-14. PubMed ID: 15917162
[TBL] [Abstract][Full Text] [Related]
20. Intrauterine levonorgestrel delivered by a frameless system, combined with systemic estrogen: acceptability and endometrial safety after 3 years of use in peri- and postmenopausal women.
Wildemeersch D; Janssens D; Schacht E; Pylyser K; de Wever N
Gynecol Endocrinol; 2005 Jun; 20(6):336-42. PubMed ID: 16019384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
